New president has 'big tent' vision for CME association

Share this article:
Damon Marquis wants to make one thing clear: CME is not the only important form of medical education.

Marquis, who formally took over this past weekend as president of the newly named Alliance for Continuing Education for the Health Professions (ACEHP), during its annual meeting, is moving aggressively to expand the group's focus beyond certified CME.

“Education for physicians cannot be done in a bubble,” he told MM&M. “Healthcare, and particularly outcomes, are improved by educating the full healthcare team.”

In addition to physicians, healthcare providers for whom Alliance members produce education include social workers, pharmacists and nurses.

The association wants to expand accordingly, by reaching out to a broader swath of stakeholders and working to ensure programs and competencies meet their needs, in line with an eight-point strategic plan passed by its board last year.

Says, Marquis, “What we are trying to do is bring everyone together under one tent.”

The Alliance is also adding two new board positions, including its first medical-device company representative, Melany Bulthuis of medical device maker Medtronic.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...